Организация медицинской помощи и лекарственного обеспечения больным несовершенным остеогенезом в Республике Башкортостан

Osteogenesis imperfecta is a group of rare hereditary diseases of connective tissue, which are based on a defective collagen formation. The main focus of the osteogenesis imperfecta drug therapy is a cyclical use of bisphosphonates (pamidronic acid). The article presents the procedure of health care and drug supply organization for children with that disease, including the development of the regulatory framework.